PharmExec Direct:
Having trouble viewing this e-mail? Click here.
PharmExec Direct | From the editors of Pharmaceutical Executive Visit the PharmExec website
Send Us Some Feedback
 
| Update My Profile | Advertise With Us | Visit PharmExec.com |
PRINT SUBSCRIBE | DIGITAL SUBSCRIBE
August 1, 2013 | ISSUE NUMBER 311 VOL 10

Special Feature
Pharm Exec’s 2013 Emerging Pharma Leaders
Meet Pharm Exec’s 15 Emerging Pharma Leaders of 2013. These trendsetters represent the future of an industry that knows it must change. The question is how, and to what? ...Read more

Global
GSK’s China Crisis: One Company, One Defining Moment
With GlaxoSmithKline the chief target of the Chinese government’s assault on corruption in the medicines, those commanding heights around CSR don’t look so high right now
...Read more

ZS Associates - Do your Oncology sales reps achieve the physician access you need to support your brands?
View this video Changing the Customer Engagement Strategy in Oncology to Improve Rep Access to hear how companies that create a positive customer experience for Oncologists are enabling conversations that impact treatment decisions.

CEO Interview
Harvey Berger, Ariad Pharmaceuticals
Harvey Berger talks with Ben Comer about the launch of his company's leukemia drug – Iclusig – and how a small cancer company can build a sustainable business by doing everything itself, from discovery to global commercializations
...Read more

Legal
The Curious Case of AstraZeneca vs. ACE
Insurance contracts are a language game that must be played very carefully, as AstraZeneca learned. Mike Kelly and Andrew Dupre report
...Read more

Legal
Court Ruling Threatens Drug Shortage Remedy
The Food and Drug Administration may no longer be able to alleviate shortages in vital drugs by permitting the import of unapproved medicines following a decision by the Court of Appeals for the District of Columbia. Jill Wechsler reports
...Read more

Orphan Drugs
Orphan Drug Adoption: the More Regulation, the Better
New survey research indicates that a country with a strong regulatory commitment for advancing drugs for rare diseases does better in getting orphan drugs to patients than countries with lesser regulatory frameworks
...Read more

Orphan Drugs
Orphan Drug Laws: A Pharmacist’s Perspective
The recent Orphan Drug Innovation Summit raised an array of interesting research questions for Temple University's Dr. Albert Wertheimer
...Read more

New eBook
The Best of the Successful Product Manager's Handbook Volume II
In the second volume of this four-volume set from the pages of Pharmaceutical Executive, learn to think outside the box to meet both timeless and newly emerging obstacles to success
...Read more

//Dr Krishna Polu, formerly of biotech firm Affymax, joined CytomX (San Francisco, CA) as Chief Medical Officer. CytomX also promoted Senior Director, Head of Business Development, Debanjan Ray, to VP, Business Development and Alliance Management. //BioSante Pharmaceuticals (Baudette, MN) named Robert Schrepfer as Vice President of New Business Development and Contract Manufacturing, effective August 12, 2013. The company also recruited Daniel Raynor to its Board of Directors. //Advanced Prenatal Therapeutics (Laguna Hills, CA) appointed Dr Nihar Nayak to Scientific Advisory Board.//Raymond L. Woosley, MD, PhD, was appointed to the board of ARCA biopharma, Inc. (Broomfield, CO).//

August 15–16: Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA.


August 19–21: 7th Annual Forum on Sunshine and Aggregate Spend
Washington DC.


September 18: Life Sciences Financial Transformation Summit
Philadelphia, PA.


 
Follow Pharm Exec on Twitter
Follow Pharm Exec on Facebook
Follow Pharm Exec on Linkedin


Survey
What is the primary social media tool you use for drug development research?

Click To Vote
 
 
Quick Links

Read the Latest Pharm Exec Global Digest

Social Media’s Not So Scary… But What About Social Business?

Compliance and Reporting: The Case for a Single System